Ampyra and Urinary tract infection - a phase IV clinical study of FDA data
Urinary tract infection is found among people who take Ampyra, especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months.
The phase IV clinical study analyzes which people take Ampyra and have Urinary tract infection. It is created by eHealthMe based on reports of 75,087 people who have side effects when taking Ampyra from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
75,087 people reported to have side effects when taking Ampyra.
Among them, 4,633 people (6.17%) have Urinary tract infection.
What is Ampyra?
Ampyra has active ingredients of dalfampridine. It is often used in multiple sclerosis. eHealthMe is studying from 75,229 Ampyra users for its effectiveness, alternative drugs and more.
What is Urinary tract infection?
Urinary tract infection is found to be associated with 4,068 drugs and 3,753 conditions by eHealthMe.
Number of Ampyra and Urinary tract infection reports submitted per year:
Time on Ampyra when people have Urinary tract infection *:
Gender of people who have Urinary tract infection when taking Ampyra*:
Age of people who have Urinary tract infection when taking Ampyra *:
Common drugs people take besides Ampyra *:
Common side effects people have besides Urinary tract infection *:
Common conditions people have *:
* Approximation only. Some reports may have incomplete information.
Do you take Ampyra and have Urinary tract infection?Check whether Urinary tract infection is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
How severe was Urinary tract infection and when was it recovered:
Expand to all the drugs that have ingredients of dalfampridine:
Alternative drugs to, pros and cons of Ampyra:
- Ampyra (75,229 reports)
Common Ampyra side effects:
- Drug ineffective: 8,776 reports
- Weakness: 6,572 reports
- Fatigue (feeling of tiredness): 6,118 reports
- Urinary tract infection: 4,633 reports
Browse all side effects of Ampyra:a b c d e f g h i j k l m n o p q r s t u v w x y z
Urinary tract infection treatments and more:
- Urinary tract infection (239,276 reports)
COVID vaccines that are related to Urinary tract infection:
- Urinary tract infection in Moderna COVID Vaccine
- Urinary tract infection in Pfizer BioNTech Covid Vaccine
- Urinary tract infection in Johnson and Johnson Covid Vaccine
Common drugs associated with Urinary tract infection:
- Prednisone: 13,893 reports
- Aspirin: 11,407 reports
- Methotrexate: 10,843 reports
- Humira: 10,333 reports
- Tysabri: 9,886 reports
- Enbrel: 8,444 reports
- Omeprazole: 8,168 reports
- Metformin: 7,296 reports
- Vitamin d: 6,742 reports
- Gabapentin: 6,625 reports
All the drugs that are associated with Urinary tract infection:
- Urinary tract infection (4,068 drugs)
Common conditions associated with Urinary tract infection:
- Multiple sclerosis: 26,759 reports
- Rheumatoid arthritis: 23,040 reports
- High blood pressure: 10,386 reports
- Pain: 6,998 reports
- Osteoporosis: 6,846 reports
All the conditions that are associated with Urinary tract infection:
- Urinary tract infection (3,753 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on dalfampridine (the active ingredients of Ampyra) and Ampyra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Cyclophosphamide and Antiphospholipid Antibodies Positive - a second ago
- Folic Acid and Myositis - 6 seconds ago
- Gemzar and Peripheral Occlusive Disease - 7 seconds ago
- Mycophenolate Mofetil and Mental Disorder Due To A General Medical Condition - 27 seconds ago
- Epanova and Cilostazol drug interaction - 31 seconds ago
- Sudafed and High Blood Cholesterol - 53 seconds ago
- Haemorrhage and drugs of ingredients of zolpidem tartrate - a minute ago
- Baclofen and Prolia drug interaction - a minute ago
- Fosamax and Failure To Thrive - a minute ago
- Ninlaro and Vitamin C drug interaction - a minute ago